» Articles » PMID: 27315033

Extending the Half-life of a Fab Fragment Through Generation of a Humanized Anti-human Serum Albumin Fv Domain: An Investigation into the Correlation Between Affinity and Serum Half-life

Overview
Journal MAbs
Date 2016 Jun 18
PMID 27315033
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

We generated an anti-albumin antibody, CA645, to link its Fv domain to an antigen-binding fragment (Fab), thereby extending the serum half-life of the Fab. CA645 was demonstrated to bind human, cynomolgus, and mouse serum albumin with similar affinity (1-7 nM), and to bind human serum albumin (HSA) when it is in complex with common known ligands. Importantly for half-life extension, CA645 binds HSA with similar affinity within the physiologically relevant range of pH 5.0 - pH 7.4, and does not have a deleterious effect on the binding of HSA to neonatal Fc receptor (FcRn). A crystal structure of humanized CA645 Fab in complex with HSA was solved and showed that CA645 Fab binds to domain II of HSA. Superimposition with the crystal structure of FcRn bound to HSA confirmed that CA645 does not block HSA binding to FcRn. In mice, the serum half-life of humanized CA645 Fab is 84.2 h. This is a significant extension in comparison with < 1 h for a non-HSA binding CA645 Fab variant. The Fab-HSA structure was used to design a series of mutants with reduced affinity to investigate the correlation between the affinity for albumin and serum half-life. Reduction in the affinity for MSA by 144-fold from 2.2 nM to 316 nM had no effect on serum half-life. Strikingly, despite a reduction in affinity to 62 µM, an extension in serum half-life of 26.4 h was still obtained. CA645 Fab and the CA645 Fab-HSA complex have been deposited in the Protein Data Bank (PDB) with accession codes, 5FUZ and 5FUO, respectively.

Citing Articles

Effectors of the Future: Universal Chimeric Antigen Receptor.

Schlegel L, Schlegel P Transfus Med Hemother. 2025; 52(1):61-76.

PMID: 39944409 PMC: 11813278. DOI: 10.1159/000539609.


Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.

Ou L, Setegne M, Elliot J, Shen F, Dassama L Chem Rev. 2025; 125(4):2120-2183.

PMID: 39818743 PMC: 11870016. DOI: 10.1021/acs.chemrev.4c00595.


Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters.

Park H, Kim K, Kim J, Kim S, Oh Y, Kang M Nat Commun. 2024; 15(1):9917.

PMID: 39557825 PMC: 11574259. DOI: 10.1038/s41467-024-53996-7.


Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species.

Harmsen M, Ackerschott B, de Smit H Front Immunol. 2024; 15:1346328.

PMID: 38352869 PMC: 10862077. DOI: 10.3389/fimmu.2024.1346328.


Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents.

Kopp A, Kwon H, Johnston C, Vance S, Legg J, Galson-Holt L Neoplasia. 2024; 48:100962.

PMID: 38183712 PMC: 10809211. DOI: 10.1016/j.neo.2023.100962.


References
1.
Sleep D, Cameron J, Evans L . Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013; 1830(12):5526-34. DOI: 10.1016/j.bbagen.2013.04.023. View

2.
Elsadek B, Kratz F . Impact of albumin on drug delivery--new applications on the horizon. J Control Release. 2011; 157(1):4-28. DOI: 10.1016/j.jconrel.2011.09.069. View

3.
Dave E, Adams R, Zaccheo O, Carrington B, Compson J, Dugdale S . Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding. MAbs. 2016; 8(7):1319-1335. PMC: 5058625. DOI: 10.1080/19420862.2016.1210747. View

4.
Flanagan R, Jones A . Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004; 27(14):1115-33. DOI: 10.2165/00002018-200427140-00004. View

5.
Clargo A, Hudson A, Ndlovu W, Wootton R, Cremin L, ODowd V . The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method. MAbs. 2014; 6(1):143-59. PMC: 3929438. DOI: 10.4161/mabs.27044. View